

11 June 2026

Dear Non-Irish Resident Creditors of Keenova Public Limited Company,

NOTICE IS HEREBY GIVEN that, at the annual general meeting of Keenova Public Limited Company (the “**Company**”) held on 2 June 2026, the following resolution was passed as a special resolution of the Company:

“*RESOLVED THAT:*

- (a) *subject to and with the consent of the Irish High Court in accordance with sections 84 and 85 of the Irish Companies Act 2014 (the “Irish Companies Act”), the entire amount (or such lesser amount as the directors of Keenova or the Irish High Court may determine) standing to the credit of Keenova’s redemption reserve account (being the undenominated capital account of Keenova created pursuant to section 106(4) of the Irish Companies Act) and share premium account as at April, 27 2026 (the “Authorized Amount”) be cancelled and extinguished such that the reserve resulting from such cancellation be treated as profits available for distribution as defined by section 117 of the Irish Companies Act 2014 (and/or any corresponding provision of any amended or replacement legislation); and*
- (b) *subject to the adoption of resolution 5(a), each director, secretary or executive officer of Keenova, be and is hereby authorized on behalf of Keenova, to proceed to seek the confirmation of the Irish High Court to a reduction of company capital by the Authorized Amount.”*

(“the **Capital Reduction**”).

The Company now proposes to apply to the High Court of Ireland for an order confirming the above resolution. The purpose of the Capital Reduction is to create additional “distributable reserves”.

A capital reduction is balance sheet neutral, in that it reduces one account (being each of the redemption reserve account and the share premium account) and increases another (the retained earnings account (which is a distributable reserve)) by a corresponding amount. As such, the Company’s net asset position will not be directly affected.

The above application will be brought by way of an Originating Notice of Motion which will be heard in the Commercial List of the Irish High Court. The date on which the hearing of the application will take place (or any change in such date) will be made available on the Investor Relations section of the Company’s website.

Should you have any queries please contact the Company’s Corporate Secretary, Mark Tyndall, in writing at Keenova Therapeutics plc, College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.

Keenova Therapeutics public limited company College Business & Technology Park +353(0)1 6960000 T
Cruiserath Road
Blanchardstown
Dublin 15
D15 TX2V
Ireland

Directors: Paul M. Bisaro (US), Leslie Donato (US), Katina J. Dorton (US), Paul Efron (US), Scott Hirsch (US), Sophia Langlois (Canada), Sigurdur Olafsson (US), Marc Yoskowitz (US), Jonathan Zinman (US)
Registered in Ireland No: 522227 Registered Office: College Business and Technology Park, Cruiserath Road, Blanchardstown, Dublin 15.

keenova

Yours faithfully,



Mark Tyndall
EVP, Chief Legal Officer & Corporate Secretary

KEENOVA THERAPEUTICS PLC

Keenova Therapeutics public limited company College Business & Technology Park +353(0)1 6960000 T
Cruiserath Road
Blanchardstown
Dublin 15
D15 TX2V
Ireland

Directors: Paul M. Bisaro (US), Leslie Donato (US), Katina J. Dorton (US), Paul Efron (US), Scott Hirsch (US), Sophia Langlois (Canada),
Sigurdur Olafsson (US), Marc Yoskowitz (US), Jonathan Zinman (US)
Registered in Ireland No: 522227 Registered Office: College Business and Technology Park, Cruiserath Road, Blanchardstown, Dublin 15.